Cargando…

Regdanvimab: First Approval

Regdanvimab (Regkirona™) is a recombinant human monoclonal antibody targeted against the severe acute respiratory syndrome coronavirus 2. It is being developed by Celltrion Inc. for the treatment of coronavirus disease 2019 (COVID-19). In September 2021, regdanvimab received full approval in South K...

Descripción completa

Detalles Bibliográficos
Autor principal: Syed, Yahiya Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558754/
https://www.ncbi.nlm.nih.gov/pubmed/34724174
http://dx.doi.org/10.1007/s40265-021-01626-7
_version_ 1784592627438452736
author Syed, Yahiya Y.
author_facet Syed, Yahiya Y.
author_sort Syed, Yahiya Y.
collection PubMed
description Regdanvimab (Regkirona™) is a recombinant human monoclonal antibody targeted against the severe acute respiratory syndrome coronavirus 2. It is being developed by Celltrion Inc. for the treatment of coronavirus disease 2019 (COVID-19). In September 2021, regdanvimab received full approval in South Korea for the treatment of COVID-19 in elderly patients aged > 50 years with at least one underlying medical condition (obesity, cardiovascular disease, chronic lung disease, diabetes, chronic kidney disease, chronic liver disease, and patients on immunosuppressive agents) and mild symptoms of COVID-19 and in adult patients with moderate symptoms of COVID-19. This article summarizes the milestones in the development of regdanvimab leading to this first approval for COVID-19. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40265-021-01626-7.
format Online
Article
Text
id pubmed-8558754
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-85587542021-11-01 Regdanvimab: First Approval Syed, Yahiya Y. Drugs AdisInsight Report Regdanvimab (Regkirona™) is a recombinant human monoclonal antibody targeted against the severe acute respiratory syndrome coronavirus 2. It is being developed by Celltrion Inc. for the treatment of coronavirus disease 2019 (COVID-19). In September 2021, regdanvimab received full approval in South Korea for the treatment of COVID-19 in elderly patients aged > 50 years with at least one underlying medical condition (obesity, cardiovascular disease, chronic lung disease, diabetes, chronic kidney disease, chronic liver disease, and patients on immunosuppressive agents) and mild symptoms of COVID-19 and in adult patients with moderate symptoms of COVID-19. This article summarizes the milestones in the development of regdanvimab leading to this first approval for COVID-19. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40265-021-01626-7. Springer International Publishing 2021-11-01 2021 /pmc/articles/PMC8558754/ /pubmed/34724174 http://dx.doi.org/10.1007/s40265-021-01626-7 Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021, corrected publication 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle AdisInsight Report
Syed, Yahiya Y.
Regdanvimab: First Approval
title Regdanvimab: First Approval
title_full Regdanvimab: First Approval
title_fullStr Regdanvimab: First Approval
title_full_unstemmed Regdanvimab: First Approval
title_short Regdanvimab: First Approval
title_sort regdanvimab: first approval
topic AdisInsight Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558754/
https://www.ncbi.nlm.nih.gov/pubmed/34724174
http://dx.doi.org/10.1007/s40265-021-01626-7
work_keys_str_mv AT syedyahiyay regdanvimabfirstapproval